MHRA authorises medicine for patients aged 12 and over with repeated flare‑ups

Funding from MJFF and Wellcome supports expansion into Parkinson’s and PTSD

Basque company becomes first authorised under new European SoHO rules

European Commission backs first ultra‑long‑acting biologic for respiratory disease

Move expands iPSC‑derived retinal model portfolio and strengthens position in research

Collaboration aims to speed access to challenging targets through an AI‑guided workflow

Bocunebart shows significant reduction in monthly migraine days in patients with previous treatment failures

New group aims to address structural barriers holding back Europe’s biotech scale‑up

FDA designation aims to speed development of new diagnostic tool

ProLectin‑M achieves 100% viral elimination by day seven in placebo‑controlled study